Anchor Capital Advisors’s GSK GSK Stock Holding History

Anchor Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,901	Closed	-$246K	–	266
2023 Q2	$246K	Sell	6,901 -688	-9%	-$24.7K	0.01%	251
2023 Q1	$270K	Sell	7,589 -3,821	-33%	-$134K	0.01%	246
2022 Q4	$401K	Sell	11,410 -1,101	-9%	-$36.7K	0.01%	224
2022 Q3	$368K	Sell	12,511 -79	-0.6%	-$2.99K	0.01%	227
2022 Q2	$685K	Sell	12,590 -306	-2%	-$16.9K	0.02%	198
2022 Q1	$702K	Sell	12,896 -632	-5%	-$34.3K	0.01%	212
2021 Q4	$746K	Sell	13,528 -1,166	-8%	-$60.7K	0.01%	202
2021 Q3	$702K	Sell	14,694 -1,516	-9%	-$76.1K	0.01%	203
2021 Q2	$807K	Sell	16,210 -6,225	-28%	-$299K	0.02%	199
2021 Q1	$1M	Sell	22,435 -195,578	-90%	-$8.88M	0.02%	181
2020 Q4	$10M	Sell	218,013 -42,498	-16%	-$1.95M	0.23%	107
2020 Q3	$12.3M	Buy	260,511 +2,035	+0.8%	+$102K	0.31%	100
2020 Q2	$13.2M	Sell	258,476 -6,116	-2%	-$314K	0.34%	98
2020 Q1	$12.5M	Sell	264,592 -12,915	-5%	-$689K	0.37%	92
2019 Q4	$16.3M	Sell	277,507 -53,574	-16%	-$2.98M	0.35%	92
2019 Q3	$17.7M	Sell	331,081 -20,310	-6%	-$1.04M	0.64%	71
2019 Q2	$17.6M	Sell	351,391 -9,747	-3%	-$489K	0.64%	73
2019 Q1	$18.9K	Sell	361,138 -62,352	-15%	-$3.12M	0.4%	71
2018 Q4	$20.2M	Sell	423,490 -15,849	-4%	-$781K	0.82%	54
2018 Q3	$22.1M	Sell	439,339 -14,923	-3%	-$758K	0.8%	55
2018 Q2	$22.9M	Sell	454,262 -53,164	-10%	-$2.68M	0.84%	48
2018 Q1	$24.8M	Buy	507,426 +74,936	+17%	+$3.49M	0.86%	47
2017 Q4	$19.2M	Sell	432,490 -39,920	-8%	-$1.84M	0.68%	68
2017 Q3	$24M	Sell	472,410 -5,885	-1%	-$299K	0.86%	47
2017 Q2	$25.8M	Sell	478,295 -12,364	-3%	-$659K	0.94%	36
2017 Q1	$25.9M	Buy	490,659 +43,115	+10%	+$2.19M	0.9%	45
2016 Q4	$21.5M	Buy	447,544 +7,900	+2%	+$390K	0.82%	53
2016 Q3	$23.7M	Sell	439,644 -134,395	-23%	-$7.37M	0.8%	53
2016 Q2	$31.1M	Buy	574,039 +270,545	+89%	+$14.3M	0.79%	51
2016 Q1	$15.4M	Sell	303,494 -1,325	-0.4%	-$66K	0.37%	83
2015 Q4	$15.4M	Sell	304,819 -25,075	-8%	-$1.28M	0.39%	80
2015 Q3	$15.9M	Sell	329,894 -11,368	-3%	-$592K	0.4%	79
2015 Q2	$17.8M	Buy	341,262 +426	+0.1%	+$24K	0.4%	83
2015 Q1	$19.7M	Sell	340,836 -33,055	-9%	-$1.9M	0.43%	84
2014 Q4	$20M	Buy	373,891 +5,585	+2%	+$312K	0.4%	84
2014 Q3	$21.2M	Buy	368,306 +16,958	+5%	+$1.04M	0.44%	84
2014 Q2	$23.5M	Buy	351,348 +72,687	+26%	+$4.92M	0.45%	80
2014 Q1	$18.6M	Buy	278,661 +44,271	+19%	+$2.99M	0.37%	90
2013 Q4	$15.6M	Buy	234,390 +9,802	+4%	+$636K	0.31%	91
2013 Q3	$14.1M	Buy	224,588 +14,429	+7%	+$929K	0.3%	86
2013 Q2	$13.1M	Buy	+210,159	New	+$13.3M	0.28%	83

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Anchor Capital Advisors's GSK Position: Q3 2023 in Review

Anchor Capital Advisors sold out of GSK (GSK) in Q3 2023, closing a stake of 6,901 shares — an estimated $246K sold.

Anchor Capital Advisors first reported a position in GSK in Q2 2013 and held it in 41 quarters. The position peaked at $31.1M in Q2 2016. 846 funds tracked by Wall St. Rank hold GSK as of Q3 2023.

Anchor Capital Advisors reported no remaining GSK position as of Q3 2023 after selling out during the quarter.
Anchor Capital Advisors sold 6,901 GSK shares in Q3 2023, an estimated $246K.
Anchor Capital Advisors first reported a position in GSK in Q2 2013 and held it in 41 quarters.
Anchor Capital Advisors's GSK position peaked at $31.1M in Q2 2016.
846 funds tracked by Wall St. Rank held GSK as of Q3 2023.

Based on Anchor Capital Advisors's 13F filing for Q3 2023, filed 9 Nov 2023.